Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 87

Sort by

Sort Order Select

Journal Articles

OPTIMIZE: A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide As GVHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Jeffery J. Auletta, Steven M. Devine, Heather E. Stefanski, Stephen R. Spellman, Todd E. Defor, Brent R. Logan, Brandan J. Butler, Mahasweta Gooptu, Brian C. Shaffer, Antonio M. Jimenez Jimenez, Sameem Abedin, Dipenkumar Modi, MHD Monzr M. Al Malki, Rachel J. Cook

Blood (2024) 144 (Supplement 1): 3514.1.

https://doi.org/10.1182/blood-2024-198252

Published: 2024

Journal Articles

Low Incidence of Chronic Graft-Versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Using Matched Related or Unrelated Donors: Phase II Study Interim Analysis

Blood (2021) 138 (Supplement 1): 1811.

https://doi.org/10.1182/blood-2021-147569

Published: 2021

Journal Articles

Icans Prophylaxis with Simvastatin and Intrathecal Dexamethasone in Adults Receiving Axicabtagene Ciloleucel (Axi‐Cel) Treatment

Joseph Maakaron, Emily Stene, Megan Bruns, Todd E. DeFor, Najla H El Jurdi, Veronika Bachanova, Daniel J. Weisdorf, Jeffrey S. Miller, Murali Janakiram, Mark Juckett

Blood (2021) 138 (Supplement 1): 1744.

https://doi.org/10.1182/blood-2021-149607

Published: 2021

Journal Articles

Gda-201, a Novel Metabolically Enhanced Allogeneic Natural Killer (NK) Cell Product Yields High Remission Rates in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL): 2-Year Survival and Correlation with Cytokine IL7

Veronika Bachanova, Joseph E. Maakaron, Frank Cichocki, David H. McKenna, Qing Cao, Todd E. DeFor, Murali Janakiram, Rose Wangen, Zuzan Cayci, Bartosz Grzywacz, Ronit Simantov, Tracey Lodie, Jeffrey S. Miller

Blood (2021) 138 (Supplement 1): 3854.

https://doi.org/10.1182/blood-2021-149989

Published: 2021

Journal Articles

Predictors and Outcomes of Flares in Chronic Graft-Versus-Host Disease

Grigori Okoev, MD PhD, Daniel J. Weisdorf, MD, John E Wagner, MD, Bruce R. Blazar, MD, Margaret L. MacMillan, MD, Todd E. DeFor, MS, Aleksandr Lazaryan, MDPhDMPH, Najla H El Jurdi, MD, Shernan G Holtan, MD, Claudio G. Brunstein, MD PhD, Brian C. Betts, MD, Takuto Takahashi, MD, Veronika Bachanova, MD PhD, Erica D. Warlick, MD, Armin Rashidi, MD PhD, Mukta Arora, MD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-136479

Published: 2020

Journal Articles

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer (NK) Cells in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma

Veronika Bachanova, MD PhD, Joseph Maakaron, MD, David H. McKenna, MD, Qing Cao, MS, Todd E. DeFor, MS, Fiona He, MD, Murali Janakiram, MD, Rose Wangen, Zuzan Cayci, MD, Bartosz Grzywacz, MD, Ronit Simantov, MD, Tracey Lodie, PhD, Jeffrey S. Miller, MD

Blood (2020) 136 (Supplement 1): 6.

https://doi.org/10.1182/blood-2020-142419

Published: 2020

Journal Articles

A Multi-Center Case Series, Systematic Review and Meta-Analysis of Neonatal Hemophagocytic Lymphohistiocytosis

Christen L. Ebens, MDMPH, Adam S DuVall, MD, Todd E. DeFor, MS, Marketa T. Dimitrov, MD, David Frame, Michael A. Briones, Michael Grimley, MD, Sarita Joshi, MBBS,MD, Rebecca A. Marsh, Evan Shereck, MD, Mark Vander Lugt, MD, James A. Connelly, MD, Kelly J. Walkovich, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-142895

Published: 2020

Journal Articles

High Incidence of Venous Thromboembolism in Patients with Chronic Graft-Versus-Host Disease

Blood (2020) 136 (Supplement 1): 44–46.

https://doi.org/10.1182/blood-2020-136337

Published: 2020

Journal Articles

Pre-Transplant Serum Claudin-3 Predicts Intestinal Graft-Versus-Host Disease and Non-Relapse Mortality Risk after Allogeneic Hematopoietic Cell Transplantation

Shernan Holtan, MD, Todd E. DeFor, MS, Armin Rashidi, MD PhD, Alexander Khoruts, MD, Christopher Staley, PhD, Lucie M Turcotte, MD, Pamala A. Jacobson, PharmD, Daniel J. Weisdorf, MD, Margaret L. MacMillan, MD

Blood (2019) 134 (Supplement_1): 39.

https://doi.org/10.1182/blood-2019-129236

Published: 2019

Journal Articles

Romiplostim Improves Platelet Recovery after UCB Transplant

Georgios E. Christakopoulos, MD, Todd E. DeFor, MS, Stefanie M Hage, RN, John E. Wagner, MD, Michael A. Linden, MD PhD, Claudio G Brunstein, MD PhD, Nelli Bejanyan, MD, Michael R Verneris, MD, Angela R. Smith, MD MS

Blood (2019) 134 (Supplement_1): 1979.

https://doi.org/10.1182/blood-2019-125424

Published: 2019

Journal Articles

Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT)

Grigori Okoev, MD PhD, Daniel J. Weisdorf, MD, John E. Wagner, MD, Bruce R. Blazar, MD, Margaret L. MacMillan, MD, Todd E. DeFor, MS, Aleksandr Lazaryan, MDPhDMPH, Najla H El Jurdi, MD, Shernan Holtan, MD, Claudio G Brunstein, MD PhD, Brian C. Betts, MD, Takuto Takahashi, MD, Veronika Bachanova, MD PhD, Erica D. Warlick, MD, Armin Rashidi, MD PhD, Mukta Arora, MD

Blood (2019) 134 (Supplement_1): 2009.

https://doi.org/10.1182/blood-2019-123421

Published: 2019

Journal Articles

Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Units (CBUs) and Promotes Faster Neutrophil Recovery and Uniform Engraftment with Potentially Less Acute Graft-Vs-Host Disease (GVHD)

Heather Stefanski, MD PhD, Claudio G Brunstein, MD PhD, David H. McKenna, MD, Darin Sumstad, MLS, Jeffrey S. Miller, MD, Bruce R. Blazar, MD, Todd E. DeFor, MS, Anthony E. Boitano, PhD, Michael P. Cooke, PhD, Glen D. Raffel, MD PhD, John C. Davis, Jr., MD MPH, MS, John E. Wagner, MD

Blood (2019) 134 (Supplement_1): 804.

https://doi.org/10.1182/blood-2019-122329

Published: 2019

Journal Articles

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)

Veronika Bachanova, MD PhD, David H. McKenna, MD, Xianghua Luo, PhD, Todd E. DeFor, MS, Fiona He, MD, Murali Janakiram, MD MS, Erica D. Warlick, MD, Rose Wangen, Zuzan Cayci, MD, Bartosz Grzywacz, MD, Guy Brachya, PhD, Tony Peled, MSc, Jeffrey S. Miller, MD

Blood (2019) 134 (Supplement_1): 777.

https://doi.org/10.1182/blood-2019-130476

Published: 2019

Journal Articles

Elevated AREG/EGF Ratio Prior to Transplantation Is Associated with Pre-Transplant Clostridium Difficile Infection, Unresolved Tissue Damage, and Poorer Overall Survival

Sarah L.P. Atkins, MD, Todd E. DeFor, MS, Margaret L. MacMillan, MD, Lucie Turcotte, MD, Armin Rashidi, MD PhD, Daniel J. Weisdorf, MD, Alexander Khoruts, MD, Shernan G. Holtan, MD

Blood (2018) 132 (Supplement 1): 3353.

https://doi.org/10.1182/blood-2018-99-115686

Published: 2018

Journal Articles

Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study

Blood (2018) 132 (Supplement 1): 71.

https://doi.org/10.1182/blood-2018-99-113564

Published: 2018

Journal Articles

Validation of Minnesota Acute GVHD Risk Score and Identification of New Factors Associated with Initial Response to Steroids: Not All GVHD Is Created Equal

Margaret L. MacMillan, MD, Shernan G. Holtan, MD, Armin Rashidi, MD PhD, Todd E. DeFor, MS, Claudio G Brunstein, MD PhD, John E. Wagner, MD, Bruce R. Blazar, MD, Daniel J. Weisdorf, MD

Blood (2018) 132 (Supplement 1): 67.

https://doi.org/10.1182/blood-2018-99-113085

Published: 2018

Journal Articles

Reduced Intensity Conditioned Bone Marrow Transplant with Post-Transplant Cyclophosphamide and Donor-Derived Mesenchymal Stromal Cell Infusions for Recessive Dystrophic Epidermolysis Bullosa

Christen L. Ebens, MD MPH, John A McGrath, MD FRCP, FMedSci, Katsuto Tamai, MD PhD, Hovnanian Alain, MD PhD, John E. Wagner, MD, Megan Riddle, Douglas R Keene, BS, Todd E. DeFor, MS, Rebecca Tryon, MS, Mei Chen, PhD, David T Woodley, MD, Kristin Hook, MD, Jakub L Tolar, MD PhD

Blood (2018) 132 (Supplement 1): 2165.

https://doi.org/10.1182/blood-2018-99-113035

Published: 2018

Journal Articles

First-in-Human Clinical Trial to Determine the Safety and Potency of Inducible T Regulatory Cells after Allogeneic Hematopoietic Cell Transplantation

Margaret L. MacMillan, MD, Keli Lee Hippen, PhD, David H. McKenna, MD, Todd E. DeFor, MS, Erica D. Warlick, MD, Claudio G Brunstein, MD PhD, Jeffrey S. Miller, MD, Daniel J. Weisdorf, MD, Bruce R. Blazar, MD, John E. Wagner, MD

Blood (2018) 132 (Supplement 1): 2112.

https://doi.org/10.1182/blood-2018-99-113100

Published: 2018

Journal Articles

Pre-Engraftment Gut Colonization with Enterococcus Casseliflavus Improves Survival after Allogeneic Hematopoietic Cell Transplantation

Armin Rashidi, MD PhD, Maryam Ebadi, MD, Robin Shields-Cutler, PhD, Todd E. DeFor, MS, Dan Knights, PhD, Daniel J. Weisdorf, MD

Blood (2018) 132 (Supplement 1): 813.

https://doi.org/10.1182/blood-2018-99-111630

Published: 2018

Journal Articles

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

Blood (2018) 131 (23): 2515–2527.

https://doi.org/10.1182/blood-2017-12-823757

Published: 2018

Includes: Supplemental data

NARROW

OPTIMIZE: A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide As GVHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Low Incidence of Chronic Graft-Versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Using Matched Related or Unrelated Donors: Phase II Study Interim Analysis

Icans Prophylaxis with Simvastatin and Intrathecal Dexamethasone in Adults Receiving Axicabtagene Ciloleucel (Axi‐Cel) Treatment

Gda-201, a Novel Metabolically Enhanced Allogeneic Natural Killer (NK) Cell Product Yields High Remission Rates in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL): 2-Year Survival and Correlation with Cytokine IL7

Predictors and Outcomes of Flares in Chronic Graft-Versus-Host Disease

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer (NK) Cells in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma

A Multi-Center Case Series, Systematic Review and Meta-Analysis of Neonatal Hemophagocytic Lymphohistiocytosis

High Incidence of Venous Thromboembolism in Patients with Chronic Graft-Versus-Host Disease

Pre-Transplant Serum Claudin-3 Predicts Intestinal Graft-Versus-Host Disease and Non-Relapse Mortality Risk after Allogeneic Hematopoietic Cell Transplantation

Romiplostim Improves Platelet Recovery after UCB Transplant

Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT)

Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Units (CBUs) and Promotes Faster Neutrophil Recovery and Uniform Engraftment with Potentially Less Acute Graft-Vs-Host Disease (GVHD)

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)

Elevated AREG/EGF Ratio Prior to Transplantation Is Associated with Pre-Transplant Clostridium Difficile Infection, Unresolved Tissue Damage, and Poorer Overall Survival

Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study

Validation of Minnesota Acute GVHD Risk Score and Identification of New Factors Associated with Initial Response to Steroids: Not All GVHD Is Created Equal

Reduced Intensity Conditioned Bone Marrow Transplant with Post-Transplant Cyclophosphamide and Donor-Derived Mesenchymal Stromal Cell Infusions for Recessive Dystrophic Epidermolysis Bullosa

First-in-Human Clinical Trial to Determine the Safety and Potency of Inducible T Regulatory Cells after Allogeneic Hematopoietic Cell Transplantation

Pre-Engraftment Gut Colonization with Enterococcus Casseliflavus Improves Survival after Allogeneic Hematopoietic Cell Transplantation

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only